Holen Sie sich die Stockscreener-App
7.84
2.00%
-0.16
Vorhandelsmarkt:
7.86
0.02
+0.26%
Schlusskurs vom Vortag:
$8.00
Offen:
$7.94
24-Stunden-Volumen:
5.98M
Relative Volume:
0.70
Marktkapitalisierung:
$2.69B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-75.80M
KGV:
-22.40
EPS:
-0.35
Netto-Cashflow:
$-68.07M
1W Leistung:
-6.33%
1M Leistung:
+68.97%
6M Leistung:
+209.88%
1J Leistung:
+189.30%
1-Tages-Spanne:
$7.80
$8.05
1-Wochen-Bereich:
$7.80
$8.9524
52-Wochen-Spanne:
$1.54
$8.9524
Nuvation Bio Inc Stock (NUVB) Company Profile
Firmenname
Nuvation Bio Inc
Sektor
Branche
Telefon
(415) 754-3517
Adresse
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
Vergleichen Sie NUVB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
7.84 | 2.74B | 0 | -75.80M | -68.07M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-19 | Eingeleitet | B. Riley Securities | Buy |
| 2025-09-30 | Eingeleitet | Jefferies | Buy |
| 2025-04-23 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-03-27 | Hochstufung | Jefferies | Hold → Buy |
| 2024-03-26 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-01-06 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-04-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-03-08 | Eingeleitet | BTIG Research | Buy |
| 2021-03-08 | Eingeleitet | Cowen | Outperform |
| 2021-03-08 | Eingeleitet | Jefferies | Buy |
| 2021-03-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Nuvation Bio Inc Aktie (NUVB) Neueste Nachrichten
Nuvation Bio Inc. $NUVB is Omega Fund Management LLC's 4th Largest Position - MarketBeat
Nuvation Bio (NUVB) price target increased by 12.48% to 10.65 - MSN
Nuvation Bio (NYSE: NUVB) partner taletrectinib added to China's 2025 NRDL - Stock Titan
Nuvation Bio (NUVB) Price Target Increased by 12.48% to 10.65 - Nasdaq
Tema Etfs LLC Purchases Shares of 139,648 Nuvation Bio Inc. $NUVB - MarketBeat
Nuvation Bio Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Nuvation Bio (NUVB) bounces back 12% on impressive clinical trial result - MSN
Why Nuvation Bio Inc. Class stock is a strong analyst pickPortfolio Update Report & Verified Momentum Stock Alerts - Newser
Cash per share of Nuvation Bio Inc. – NYSE:NUVB - TradingView
Will Nuvation Bio Inc. Warrants stock profit from AI boom2025 Risk Factors & Technical Buy Zone Confirmations - Newser
Insider Selling: Nuvation Bio (NYSE:NUVB) Insider Sells 150,000 Shares of Stock - MarketBeat
Why millennials buy Nuvation Bio Inc. Warrants stockJuly 2025 Summary & Risk Managed Investment Signals - Newser
Nuvation Bio (NUVB) Bounces Back 12% on Impressive Clinical Trial Result - Insider Monkey
Nuvation Bio (NYSE:NUVB) Stock Price Up 8.9%Still a Buy? - MarketBeat
NUVB SEC FilingsNuvation Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Nuvation Bio’s chief medical officer sells $1.17 million in stock By Investing.com - Investing.com South Africa
Nuvation Bio (NYSE:NUVB) Hits New 1-Year HighHere's What Happened - MarketBeat
Nuvation Bio Inc. (NYSE:NUVB) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Will Nuvation Bio Inc. Class stock profit from AI boomJuly 2025 Selloffs & Trade Opportunity Analysis Reports - Newser
10 Stocks Stealing Market Spotlight - Insider Monkey
Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology - Investing News Network
Nuvation Bio’s Surge: Buy or Observe? - StocksToTrade
ETFs Investing in Nuvation Bio Inc. Stocks - TradingView
Nuvation Bio’s chief medical officer sells $1.17 million in stock - Investing.com
Nuvation Bio Insider Sold Shares Worth $1,173,255, According to a Recent SEC Filing - marketscreener.com
Nuvation Bio (NUVB) Chief Medical Officer reports 150K share sale and option exercise - Stock Titan
Nuvation Bio stock hits 52-week high at $8.24 - Investing.com
Nuvation Bio stock hits 52-week high at $8.24 By Investing.com - Investing.com Nigeria
NUVB: Iptrozi and Safusidenib show strong clinical and commercial momentum, driving major growth potential - TradingView
NUVB: Iptrozi and Safusidenib drive strong growth, with robust financials and pipeline innovation - TradingView
Nuvation Bio: Phase 2 study results in IDH1-mutant gliomas published - Traders Union
Will Nuvation Bio Inc. Warrants stock benefit from sector leadershipWeekly Loss Report & Real-Time Volume Analysis - Newser
Geode Capital Management LLC Acquires 864,194 Shares of Nuvation Bio Inc. $NUVB - MarketBeat
Will Nuvation Bio Inc. Class stock outperform benchmarks2025 Big Picture & Long-Term Growth Stock Strategies - Newser
Can Nuvation Bio Inc. Class stock surprise markets with earningsPortfolio Gains Summary & Stepwise Entry/Exit Trade Alerts - Newser
Is Nuvation Bio Inc. stock a safe buy before earningsTreasury Yields & AI Enhanced Market Trend Forecasts - Newser
Officer Liu Files To Sell 150,000 Of Nuvation Bio Inc [NUVB] - TradingView
H.C. Wainwright reiterates Buy rating on Nuvation Bio stock at $10 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy rating on Nuvation Bio stock at $10 target - Investing.com Canada
HC Wainwright & Co. Reiterates Nuvation Bio (NUVB) Buy Recommendation - Nasdaq
What is Wedbush's Estimate for Nuvation Bio FY2027 Earnings? - MarketBeat
Truist Financial Sticks to Their Buy Rating for Nuvation Bio (NUVB) - The Globe and Mail
Nuvation Bio’s Strategic Dilemma: Navigating Taletrectinib’s Global Commercialization Risks - MSN
Nuvation Bio: A Strong Company Now Fairly Priced - Seeking Alpha
Top Growth Companies With Strong Insider Ownership November 2025 - simplywall.st
Nuvation Bio (NUVB) Halts NUV-1511 and Highlights Safusidenib Data Is Strategic Focus Shifting? - Yahoo Finance
Nuvation Bio (NUVB): Exploring Valuation After a 52% One-Month Rally - Yahoo Finance
Insider Selling: Nuvation Bio (NYSE:NUVB) Insider Sells 10,000 Shares of Stock - MarketBeat
Nuvation Bio to discontinue development of NUV-1511 - MSN
Finanzdaten der Nuvation Bio Inc-Aktie (NUVB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):